Search results
Karuna is the Sanskrit word for action taken to diminish the suffering of others. We are dedicated to championing the needs and experiences of people living with mental illness as we work toward our mission of developing and delivering transformative medicines for those in need.
We are a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. We pride ourselves on our deep expertise in neuroscience and inventive thinking around drug discovery and development.
Discover Karuna Group: a dynamic conglomerate driving innovation in distribution, retail, manufacturing, healthcare, and finance. Guided by compassion and excellence, we redefine industries, transform lives, and create a brighter, prosperous future together.
Mar 18, 2024 · With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq Global Select Market and Karuna is now a wholly owned subsidiary of Bristol Myers Squibb (“BMS”).
Dec 22, 2023 · Karuna is a biopharmaceutical company driven to discover, develop and deliver transformative medicines for people living with psychiatric and neurological conditions. Karuna's lead asset, KarXT (xanomeline-trospium), is an antipsychotic with a novel mechanism of action (MoA) and differentiated efficacy and safety.
Dec 22, 2023 · Bristol Myers Squibb, the global pharmaceutical giant, said on Friday that it would acquire Karuna Therapeutics, which makes drugs to treat schizophrenia and Alzheimer’s, in an all-cash deal...
karuna means “compassion in action.” Through deepening our understanding of these complex conditions, our goal is to develop medicines that can alleviate burdensome symptoms to help restore function to those living with serious mental illness. We also continue to advance an earlier stage pipeline of muscarinic
Oct 4, 2023 · Karuna's Andrew Miller details the long journey to get KarXT from Eli Lilly’s storeroom all the way to the FDA for schizophrenia.
Dec 26, 2023 · Bristol Myers Squibb (BMS) has signed a definitive agreement for the acquisition of all outstanding shares of common stock of biopharmaceutical company Karuna Therapeutics for an equity value totalling $14bn in cash. The new strategic merger deal is part of BMS’ strategy to bolster its neuroscience portfolio.
Karuna Therapeutics | 26,502 followers on LinkedIn. Pushing the boundaries of neuroscience to transform the treatment of mental illness. | Karuna Therapeutics, Inc. is now part of Bristol Myers...
